How the LDT Final Rule’s Exemptions Apply to Oncology Labs
Regulatory expert explores whether any exclusions might benefit cancer laboratories trying to navigate upcoming compliance deadlines
Regulatory expert explores whether any exclusions might benefit cancer laboratories trying to navigate upcoming compliance deadlines
Seven months into the year, there were already four reported deals valued at over $1 billion in 2023, as many as in all of 2022.
Proposed rule would require businesses to undergo even more stringent review to secure regulatory approval for such deals.
Recent advisory opinion offers insight on how healthcare providers may want to structure arrangements involving online directories.
Inadequate CMS oversight resulted in $888.2 million in improper payments for the highest reimbursing molecular pathology genetic tests, report says.
The proposed PFS rule also includes other changes that will affect physician, lab, and other reimbursements in 2024 and beyond.
Recently proposed rule seems too stringent to reduce the lag between FDA approval and Medicare coverage.
Centers for Medicare & Medicaid Services proposes TCET pathway to expedite Medicare Coverage of newly approved breakthrough devices.
Deciding whether to purchase or lease laboratory instrumentation involves a variety of factors.
Release of second-generation Cologuard test data and recently announced partnerships aim to position company well for the future.
Diagnostics companies that invested heavily in COVID-19 products are relying on M&A transactions to restructure and transition.